In an iterative phase 2 trial, patients with metastatic, treatment-refractory, mismatch repair proficient gastrointestinal cancers had responses to neoantigen-reactive tumor-infiltrating lymphocytes but not bulk tumor-infiltrating lymphocytes, highlighting the potential for a refined immune cell therapy approach in this patient population.
- Frank J. Lowery
- Stephanie L. Goff
- Steven A. Rosenberg